TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A narrative review published November 5 argues that chronic neuropathic pain after critical illness may be underrecognized and should be distinguished from other post-ICU pain. The authors say neuromodulation could merit study for selected patients, but there is not enough direct evidence to establish its effectiveness in ICU survivors.
A narrative review published November 5 is calling for more targeted diagnosis of chronic neuropathic pain in people who survive intensive care, while proposing that neuromodulation be studied for selected patients whose symptoms remain disabling. The authors stress that neuromodulation has not been established as a treatment for post-ICU neuropathic pain; direct evidence in this population is insufficient.
The review, titled Neuromodulation for Refractory Neuropathic Pain Following Critical Illness: A Narrative Review and Phenotype-Based Clinical Framework, was written by Suresh Srinivasan, Kiran Khurshid, Uzam Hussain, Joseph Pathakamuri and Mohanraj Palani Selvam. The authors argue that pain deserves greater recognition among the ongoing problems some people face after an ICU stay, alongside weakness, mobility limitations, sleep disruption, cognitive difficulties and psychological distress.
They cite a 2026 meta-analysis estimating chronic pain incidence at about 47% three months after critical illness, 29% at six months and 31% at 12 months. Those figures refer to chronic pain overall, not specifically neuropathic pain. In a separate prospective multicenter cohort of 814 patients, nearly 48% reported significant persistent pain three months after ICU admission; among those with pain, about 9% screened positive for neuropathic symptoms. The authors caution that studies differ in populations, definitions and follow-up periods.
The review distinguishes nerve-related pain from musculoskeletal pain that can follow immobility, muscle injury, procedures or deconditioning. It also warns that weakness alone does not establish neuropathic pain: critical illness polyneuropathy affects nerves, while critical illness myopathy primarily affects muscle. The authors say treatment decisions should follow assessment of the likely source of symptoms.
Why Accurate Pain Diagnosis Matters
Distinguishing neuropathic symptoms from other causes of pain matters because a broad label of “post-ICU pain” may not identify which treatment fits a patient’s condition. The review says rehabilitation, physical therapy, psychological support, sleep care and individualized medication remain important parts of recovery. It does not suggest that these approaches should be replaced by implanted or electrical therapies.
The authors note that medicines sometimes used for neuropathic pain, including gabapentinoids, certain antidepressants and topical treatments, may be difficult for some recovering patients to tolerate. They cite possible concerns such as renal dysfunction, cognitive impairment, dizziness, sedation and respiratory vulnerability. These are considerations for individualized clinical decisions, not a claim that such medicines are unsuitable for every ICU survivor.
Persistent pain can also interfere with participation in rehabilitation, the review says. Its call is to recognize and characterize symptoms earlier, and to investigate additional options when pain remains disabling despite appropriate conventional care. The potential impact is therefore twofold: more precise assessment could clarify the problem, while research could determine whether targeted interventions help particular patient groups.
Products Worth Considering
Hyperice Hypervolt Go 3 Portable Percussion Massage Gun with Carry Case
Therabody Theragun Relief Massage Gun – Black
Therabody Theragun Prime 6th Generation Deep Tissue Massage Gun, Navy
As an affiliate, we earn on qualifying purchases.
What the Review Builds On
The article is an opinion piece accompanying a narrative review, not a clinical trial of neuromodulation in ICU survivors. It draws on existing work about post-intensive care syndrome, chronic pain after critical illness and neuromodulation for other conditions. The cited systematic review found persistent pain frequencies ranging from 28% to 77%; the authors attribute that wide range to differences in study populations, definitions and follow-up periods.
The proposed framework considers three approaches: peripheral nerve stimulation (PNS) for potentially focal nerve injuries; dorsal root ganglion stimulation (DRGS) for selected regional pain presentations; and spinal cord stimulation (SCS) for some bilateral or multisegmental patterns. These are proposed research directions based on pain phenotype, not established recommendations for ICU survivors.
The authors point to trials involving other patient groups, including the ACCURATE trial of DRGS versus conventional SCS in lower-extremity complex regional pain syndrome or causalgia, and the SENZA-PDN trial of 10-kHz SCS for refractory painful diabetic neuropathy. Those findings cannot establish that the same therapies work after critical illness, because the populations and conditions differ.
“We need to identify neuropathic pain earlier, understand its underlying mechanisms, and investigate treatment strategies beyond conventional pharmacotherapy when symptoms remain disabling.”
— The review authors
Evidence Gaps in ICU Survivors
The central uncertainty is whether any form of neuromodulation is safe and effective for chronic neuropathic pain specifically after critical illness. The review says direct clinical evidence is insufficient to establish effectiveness in this population. Results from trials in diabetic neuropathy, complex regional pain syndrome or causalgia cannot be assumed to apply to ICU survivors.
It is also unclear how many people with persistent post-ICU pain have neuropathic pain confirmed through clinical assessment rather than a screening questionnaire. The figures cited by the authors come from studies with varying methods, and the review describes several possible causes of symptoms. The source material does not provide a trial showing that the proposed phenotype-based approach improves diagnosis or outcomes.
The article does not set out a new clinical guideline, treatment approval or recommendation to use stimulation devices after an ICU stay. Which patients might benefit, what treatment targets are appropriate, and how benefits and risks compare with standard care remain questions for future research.
Research Needed Before Wider Use
The next step identified by the authors is clearer evaluation of persistent pain after critical illness, including assessment of whether symptoms are neuropathic and what nerve or region may be involved. They argue that research should connect each proposed neuromodulation approach to a clearly defined pain pattern rather than treating post-ICU pain as a single condition.
Studies would need to test these interventions directly in carefully selected ICU survivors and report outcomes and risks. Until such evidence is available, the review presents PNS, DRGS and SCS as potential avenues for investigation, not proven post-ICU treatments. The authors’ immediate emphasis remains earlier identification and individualized care.
Key Questions
How common is chronic pain after an ICU stay?
The review cites a 2026 meta-analysis estimating chronic pain incidence at 47% at three months, 29% at six months and 31% at 12 months. These estimates cover chronic pain overall, not neuropathic pain alone, and studies used different populations and methods.
Does persistent pain after critical illness mean nerve damage?
No. The review says post-ICU pain can have musculoskeletal, procedural or nerve-related causes. It emphasizes that weakness by itself does not prove neuropathic pain and that assessment should identify the likely source.
Is neuromodulation proven for ICU survivors?
No. The authors say there is insufficient direct clinical evidence to establish neuromodulation’s effectiveness for neuropathic pain after critical illness. Evidence from other conditions does not confirm benefit in this group.
Which neuromodulation methods does the review discuss?
It proposes studying peripheral nerve stimulation, dorsal root ganglion stimulation and spinal cord stimulation for different pain patterns. These are research possibilities, not established post-ICU treatment recommendations.
What should happen next?
The review calls for earlier identification of neuropathic symptoms and direct studies in carefully selected ICU survivors. It does not announce a new trial or provide a timeline for when such evidence may become available.
Source: medpagetoday.com
